PolyPid reported a FY 2025 operating loss of USD 33.0 million and a FY 2025 net loss of USD 34.2 million, with loss before income tax of USD 34.2 million and income tax expense of USD 5,000. FY 2025 operating expenses included R&D of USD 23.8 million, marketing and business development of USD 2.0 million, and G&A of USD 7.2 million. Financial expense, net was USD 0.7 million in FY 2025, and the company also recorded a USD 0.5 million loss on extinguishment of debt. PolyPid said it has not generated any revenue from product sales and does not expect product-sales revenue for the foreseeable future. The company ended FY 2025 with USD 12.9 million in cash and cash equivalents and short-term deposits, and an accumulated deficit of USD 301.5 million. Net cash used in operating activities was USD 27.9 million in FY 2025, while net cash used in investing activities was USD 6.7 million and net cash provided by financing activities was USD 25.4 million. On the business front, PolyPid highlighted continued work toward regulatory filings for D-PLEX100, including NDA submission activities, and said it expects existing cash to fund operations into the second half of 2026. The company also capitalized USD 1.1 million of pre-launch inventories as of December 31, 2025, citing its assessment of the regulatory process for D-PLEX100 (with an NDA to be submitted on a rolling basis beginning by the end of Q1 2026). PolyPid also noted it continues preclinical development of its OncoPLEX oncology program and reported that, as of February 25, 2026, its patent estate included 157 issued patents, one allowed patent application and 18 pending patent applications.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-020370), on February 25, 2026, and is solely responsible for the information contained therein.
Comments